Continuation of Milnacipran Therapy During Pregnancy in a Patient with Severe PTSD

Overview

This case study discusses the challenges of managing severe PTSD and psychotic depression during pregnancy, highlighting the use of milnacipran. Despite limited safety data, the patient experienced significant improvement with milnacipran, underscoring the complexities of treatment decisions in this context.

Background

Pharmacological treatment of mental health disorders during pregnancy is crucial, as untreated conditions can lead to severe maternal and fetal risks. Antidepressant discontinuation can increase relapse rates, particularly in women with severe psychiatric histories. Milnacipran, an SNRI, has limited pregnancy safety data, complicating treatment decisions for clinicians.

Data Highlights

No numerical data available in the article.

Key Findings

• Milnacipran was effective in managing severe PTSD and psychotic depression before pregnancy.
• Switching to sertraline and quetiapine led to a rapid relapse of depressive symptoms.
• After a risk-benefit evaluation, milnacipran was resumed with renewed clinical improvement.
• Moderate hyperemesis gravidarum led to discontinuation of milnacipran by gestational week 22.
• No congenital anomalies or neonatal adaptation issues were reported at delivery.
• Pediatric developmental screenings at 3-year follow-up were within expected limits.

Clinical Implications

Clinicians must weigh the risks of medication discontinuation against the potential for relapse in severe psychiatric conditions during pregnancy. Shared decision-making is essential when considering the continuation of medications like milnacipran, especially in the absence of robust safety data.

Conclusion

This case illustrates the delicate balance required in managing severe psychiatric conditions during pregnancy, emphasizing the need for individualized treatment approaches based on patient history and clinical response.

References

1. BMC Psychiatry (Springer), 2023 -- Linking Treatment of Perinatal Mood and Anxiety Disorders to Infant Outcomes in Privately Insured Populations
2. Drugs - Real World Outcomes, 2021 -- Antidepressant Administration in Pregnant Women and Its Possible Impact on Motor Skills and Cognitive Development in Children: A Comprehensive Review
3. BMC Psychiatry (Springer), 2025 -- Treatment persistence and modification patterns of SSRIs in children and adolescents with depression: a nationwide population-based study in South Korea
4. Drug Safety, 2023 -- Impact of Prenatal Pregabalin Exposure on Birth Outcomes and Neurodevelopment: A Cohort Analysis Across Four Nordic Nations
5. ONG-23-580 1262..1288, 2025 -- ACOG Clinical Practice Guideline No. 5
6. Perinatal Mental Health Care Guide
7. ONG-23-580 1262..1288
8. Duloxetine Exposure During Pregnancy and the Risk of Offspring Being Born Small for Gestational Age or Prematurely: A Nationwide Danish and Swedish Safety Study - PMC